Chemotherapy-Induced Anemia Market to Grow with a CAGR of 6.83% through 2028

Rising Incidence of Cancer and expanding geriatric population are factors driving the global Chemotherapy-Induced Anemia market in the forecast period 2024-2028.

According to TechSci Research report, “Chemotherapy-Induced Anemia Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Chemotherapy-Induced Anemia Market stood at USD 2.66 Billion in 2022 and is anticipated to grow with a CAGR of 6.83% in the forecast period, 2024-2028. The global chemotherapy-induced anemia market has witnessed significant growth in recent years, driven by various factors that have transformed the landscape of cancer treatment. Chemotherapy-induced anemia is a common side effect of cancer therapy, affecting a substantial portion of cancer patients. One of the primary drivers behind the growth of the chemotherapy-induced anemia market is the increasing incidence of cancer worldwide. According to the World Cancer Research Fund, cancer cases are expected to rise by 63% in the next two decades. As more individuals are diagnosed with cancer and undergo chemotherapy, the prevalence of chemotherapy-induced anemia is also expected to increase, driving the demand for treatment options.

 Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Chemotherapy-Induced Anemia Market.”

Advancements in cancer treatment have improved the survival rates of cancer patients. These advancements include targeted therapies, immunotherapies, and precision medicine. While these treatments offer promising outcomes, they often come with side effects, including anemia. Consequently, the need for effective anemia management solutions has grown alongside these therapeutic advances. The global population is aging, with a growing number of elderly individuals. Aging is a significant risk factor for cancer, and older adults are more likely to experience chemotherapy-induced anemia. This demographic shift is contributing to the expansion of the chemotherapy-induced anemia market, as it leads to a larger pool of potential patients requiring treatment.

There is a growing awareness among healthcare providers and patients about the impact of chemotherapy-induced anemia on the quality of life and overall health of cancer patients. Healthcare professionals are now more proactive in diagnosing and managing anemia in cancer patients, creating a greater demand for anemia treatments.

The Global Chemotherapy-Induced Anemia Market is segmented into disease type, treatment type, drug type,  end user and company.

Based on end user, the hospitals segment has emerged as the predominant market leader. Hospitals and clinics often engage in research and clinical trials aimed at advancing our understanding of chemotherapy-induced anemia and developing more effective treatments. This commitment to research contributes to the development of new therapies and treatment guidelines. Based on region, North America segment is expected to grow during the forecast period.  The pharmaceutical industry in North America plays a pivotal role in addressing chemotherapy-induced anemia. Leading pharmaceutical companies headquartered in the United States and Canada are at the forefront of developing anemia management drugs, including erythropoiesis-stimulating agents (ESAs) and iron supplements. These companies have a global reach, ensuring that their products are accessible to patients around the world. North America boasts a robust regulatory framework that ensures the safety and efficacy of medications used to manage chemotherapy-induced anemia. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and Health Canada have stringent approval processes in place, instilling confidence in patients and healthcare providers regarding the quality and safety of anemia management products.

The Asia Pacific region is experiencing rapid market growth. The high cancer incidence rates in the region contribute to the region's dominance in the CIA market. With millions of cancer patients receiving chemotherapy each year, there is a constant demand for anemia management solutions. This sizable patient population makes Asia Pacific an attractive market for pharmaceutical companies and healthcare providers.

Major companies operating in Global Chemotherapy-Induced Anemia Market are:

• Dr. Reddy's Laboratories Ltd
• Pfizer Inc
• Panacea Biotec Limited
• SBI PHARMACEUTICALS CO., LTD
• Tolero Pharmaceuticals, Inc.
• Vifor Pharma AG
• Therapure Biopharma Inc.
• PharmaEssentia Corp.
• PhytoHealth Corp
• UBI Pharma Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The global chemotherapy-induced anemia market is experiencing robust growth due to several key drivers, including the rising incidence of cancer, advancements in cancer treatment, an aging population, increased awareness, innovative drug development, evolving reimbursement policies, and the shift towards patient-centric care. These factors collectively contribute to the expanding market for therapies aimed at managing chemotherapy-induced anemia, improving the quality of life for cancer patients, and enhancing their overall treatment experience.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Chemotherapy-Induced Anemia Market By Disease Type (Mild Anemia, Moderate Anemia, Severe Anemia), By Treatment Type (RBC Transfusions, Erythropoiesis-stimulating agents (ESAs), Iron Supplementation), By Drug Type (Epogen Injection, Procrit Injection, Androxy Oral, Aranesp injection, Epoetin Alfa Injection, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global Chemotherapy-Induced Anemia Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Chemotherapy-Induced Anemia Market.

Contact

Mr. Ken Mathews         

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656                                                     

Email: [email protected]               

Website: www.techsciresearch.com